Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.82 |
| ▸ | RAF1 | P04049 | 8/20 | 0.82 |
| ▸ | BRAF | P15056 | 6/20 | 0.82 |
| ▸ | RET | P07949 | 4/20 | 0.82 |
| ▸ | ABL1 | P00519 | 4/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.82 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.82 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.82 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.82 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.82 |
| ▸ | HTR1A | P08908 | 2/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.82 |
| ▸ | KIT | P10721 | 2/20 | 0.82 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.82 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.82 |
| ▸ | FLT1 | P17948 | 2/20 | 0.82 |
| ▸ | MAOA | P21397 | 2/20 | 0.82 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5080020 | 0.93 | KDR (0.85) | KDRRAF1BRAFRETABL1 | |
| SCHEMBL13885368 | 0.91 | RAF1 (0.80) | KDRRAF1BRAFRETABL1 | |
| Regorafenib SCHEMBL29351376 | 0.90 | RAF1 (1.00) | KDRRAF1BRAFRETABL1 | |
| Regorafenib SCHEMBL29349808 | 0.90 | RAF1 (1.00) | KDRRAF1BRAFRETABL1 | |
| Regorafenib SCHEMBL432230 | 0.90 | RAF1 (1.00) | KDRRAF1BRAFRETABL1 | |
| SCHEMBL5082237 | 0.90 | RAF1 (0.83) | KDRRAF1BRAFRETABL1 | |
| Regorafenib SCHEMBL29555444 | 0.90 | RAF1 (0.98) | KDRRAF1BRAFRETABL1 | |
| Regorafenib SCHEMBL2555101 | 0.90 | RAF1 (0.98) | KDRRAF1BRAFRETABL1 | |
| Regorafenib SCHEMBL29496390 | 0.90 | RAF1 (0.98) | KDRRAF1BRAFRETABL1 | |
| Regorafenib SCHEMBL2554008 | 0.90 | RAF1 (0.98) | KDRRAF1BRAFRETABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180214449-A1 | CANCER THERAPY USING JAK INHIBITOR IN COMBINATION WITH MAPK INHIBITORS | UBRX, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | KDR 1464/4885RAF1 2627/4885BRAF 3140/4885 |
| US-20180214449-A1 | CANCER THERAPY USING JAK INHIBITOR IN COMBINATION WITH MAPK INHIBITORS | JAK2, JAK1, JAK3 | KDR 1375/4885RAF1 98/4885BRAF 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.